Accessible version Fulcrum Therapeutics FULC to merge with Slate Medicines; Move to No Rating Rating Change: NO RATING | PO: NA | Price: 3.84 USD Slate Medicines to enter the clinic with migraine drug FULC announced a merger agreement with Slate Medicines, an early clinical-stage therapeutics company developing antibody therapies for migraine and other headache disorders, expected to close in 4Q26. Recall, FULC's Board of Directors was reviewing strategic alternatives following the discontinuation of the po ...